Printer Friendly

Abeona Therapeutics reports Q2 EPS (49c), consensus (35c).

Cash, cash equivalents and marketable securities as of June 30, 2019, were $62.5M compared to $68.3M as of March 31, 2019. The decrease in cash was driven primarily by the net cash used in operating activities of $15.2M. "The second quarter was highlighted by progress made in both of our MPS III programs," said Joao Siffert, M.D., Chief Executive Officer. "Data from our Transpher A study showed that children with MPS IIIA who were treated early with ABO-102 preserved neurocognitive development within the normative range 12-18 months post treatment. Our MPS IIIB program has also progressed, with enrollment of additional patients in cohort 2 of the Transpher B study. Our team remains highly focused on our lead programs, including the start of our VIITAL Phase 3 clinical trial in recessive dystrophic epidermolysis bullosa, continued enrollment in the MPS III programs, and preparations to start the clinical trial in CLN1 disease."

COPYRIGHT 2019 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Article Type:Financial report
Date:Aug 9, 2019
Words:154
Previous Article:Amgen 'pleased' with decision in Sandoz patent case.
Next Article:J. Alexander's expands review of strategic alternatives.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters